Cost-effectiveness of Evolocumab

Rev Esp Cardiol (Engl Ed). 2018 Dec;71(12):1089. doi: 10.1016/j.rec.2018.04.028. Epub 2018 Jul 7.
[Article in English, Spanish]
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Cost-Benefit Analysis
  • Ezetimibe
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors*
  • Hypercholesterolemia*
  • Proprotein Convertase 9
  • Spain

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Proprotein Convertase 9
  • Ezetimibe
  • evolocumab